Bolin Liu, MD

Publications

• Xiaoping Huang, Shuiliang Wang, Choon-Kee Lee, XiaoHe Yang, and Bolin Liu. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Letters 2011 Aug 1;307(1):72-9. doi:10.1016/j.canlet.2011.03.019
• Ma J, Wang S, Zhao M, Deng XS, Lee CK, Yu XD, Liu B. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. BMC Cancer 2011 Jun 16;11(1):255.
• Bolin Liu,* Zeying Fan, Susan M. Edgerton, XiaoHe Yang, Stuart E. Lind, and Ann D. Thor*. Potent Anti-proliferative Effects of Metformin on Trastuzumab-resistant Breast Cancer Cells via Inhibition of ErbB2/IGF-1 Receptor Interactions. Cell Cycle Sep 1, 10 (17): 2959-2966, 2011 *Corresponding authors
• Yuhua Zhao, Hao Liu, Zixing Liu, Yan Ding, Susan P. LeDoux, Glenn L. Wilson, Richard Voellmy, Yifeng Lin, Wensheng Lin, Rita Nahta, Bolin Liu, Oystein Fodstad, Jieqing Chen, Yun Wu, Janet E. Price, and Ming Tan. Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism. Cancer Research 71(13): 4585-4597, 2011; DOI:10.1158/0008-5472.
• Bo Cai, Shuiliang Wang, Jingcao Huang, Choon-Kee Lee, Chunji Gao, and Bolin Liu. Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. American Journal of Translational Research 2013; 5(1):36-46.
• Wang, L., Huang, Z., Lin H., Li, Z., Hetzel, F.W., and Liu, B. Effects of photofrin-mediated photocytotoxicity on a panel of human pancreatic cancer cells. Photodiagnosis and Photodynamic Therapy, 2013 http://dx.doi.org/10.1016/j.pdpdt.2012.11.001.
• Shuiliang Wang, Jingcao Huang, Hui Lyu, Choon-Kee Lee, Jianming Tan, Jianxiang Wang, and Bolin Liu. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death & Disease (2013) 4, e556; doi:10.1038/cddis.2013.79
• Bo Cai, Hui Lyu, Jingcao Huang, Shuiliang Wang, Choon-Kee Lee, Chunji Gao, and Bolin Liu. Combination of Bendamustine and Entinostat Synergistically Inhibits Proliferation of Multiple Myeloma Cells via Induction of Apoptosis and DNA Damage Response. Cancer Letters 2013; 335 (2): 343-350. http://dx.doi.org/10.1016/j.canlet.2013.02.046
• Shuiliang Wang, Jingcao Huang, Hui Lyu, Bo Cai, Xiaoping Yang, Fang Li, Jianming Tan, Susan M. Edgerton, Ann D Thor, Choon-Kee Lee, and Bolin Liu. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Research 2013; 15:R101. doi:10.1186/bcr3563
• Jingcao Huang, Shuiliang Wang, Hui Lyu, Bo Cai, XiaoHe Yang, Jianxiang Wang, and Bolin Liu. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Molecular Cancer 2013; 12:134 doi:10.1186/1476-4598-12-134
• Reema Wahdan-Alaswad and Bolin Liu. “Sister” miRNAs in cancers. Cell Cycle 2013; 12 (24): 3703-3704
• Wahdan-Alaswad, R., Fan, Z., Edgerton, S.M., Liu, B., Deng, X-S., Arnadottir, S.S., Richer, J.K., Anderson, S.M., and Thor, A.D. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle 2013; 12(24): 3759-3769
• Deng Y, Deng H, Liu J, Han G, Malkoski S, Liu B, Zhao R, Wang XJ, Zhang Q. Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer. Molecular Carcinogenesis 2011 Jun 16. doi: 10.1002/mc.20813.
• Andrew Milgroom, Miranda Intrator, Krishna Madhavan, Luciano Mazzaro, Robin Shandas, Bolin Liu, Daewon Park. Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent. Colloids Surf. B: Biointerfaces (2013) http://dx.doi.org/10.1016/j.colsurfb.2013.10.038
• Lyu, H., Huang, JC, Wang, S., Yang, XP, Edgerton, S.M., Thor, A.D., and Liu, B. The erbB3 blocking antibody MM-121 overcomes resistance and enhances efficacy of paclitaxel against erbB2-overexpressing breast cancer. Postdoctoral Research Day, University of Colorado Anschutz Medical Campus, March 22, 2013
• Jiemiao Hu, Xinli Liu, Dennis Hughes, Francisco J. Esteva, Bolin Liu, Joya Chandra, Shulin Li. Herceptin Conjugates via EDC Boost Direct Tumor Cell Death via Programmed Tumor Cell Necrosis. PloS One 2011; 6(8):e23270. PMID: 21853100 PMCID: PMC3154407
• Yuping Mei, Jeipi Liao, Jun Shen, Lei Yu, Bolin Liu, Ruiyun Li, Lin Ji, Susan G Dorsey, Zhenran Jiang, Ruth L Katz, Jian-Ying Wang, and Feng Jiang. Small nucleolar RNA 42 (SNORA42) acts as an oncogene in lung tumorigenesis. Oncogene 2011 Oct 10. doi: 10.1038/onc.2011.449. PMID: 21986946
• Xin-Sheng Deng, Shuiliang Wang, Anlong Deng, Bolin Liu, Susan M. Edgerton, Stuart E. Lind, Reema Wahdan-Alaswad and Ann D. Thor. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple negative breast cancers. Cell Cycle 11:2, 367-376; January 15, 2012
• Wahdan-Alaswad R., Fan Z., Arnadottir S., Edgerton SM, Liu B., Thor AD. Deleterious Cross Talk between Estrogen and Thyroid Signaling in Enhances Stem Cell Population in Luminal Breast Cancers. (First-place award) Conference on Women’s Health Research. School of Medicine, University of Colorado Anschutz Medical Campus, Oct 17th, 2013
• Wang, S., Huang, X., Lee, C-K., and Liu, B. Expression of erbB3 upregulates Survivin via transcription-independent mechanism in erbB2-overexpressing breast cancer cells to confer Paclitaxel resistance (A1710). Proceedings of AACR, 2011.
• Jingcao Huang, Hui Lyu, Youngseok Lee, and Bolin Liu. The erbB3 blocking antibody MM-121 re-sensitizes trastuzumab-resistant breast cancer cells to trastuzumab-mediated antitumor activity in vitro and in vivo. The AACR Special Conference on Advances in Breast Cancer Research. San Diego, CA, Oct 3-6, 2013.
• Hui Lyu, Jingcao Huang, Youngseok Lee, and Bolin Liu. Differential effects of erbB3 and IGF-1R signaling on lapatinib resistance acquired by the erbB2-overexpressing breast cancer cells refractory to trastuzumab. The AACR Special Conference on Advances in Breast Cancer Research. San Diego, CA, Oct 3-6, 2013.
• Wang, S., Huang, J., Lee, C-K., and Liu, B. Epigenetic targeting of erbB2/erbB3 receptors via functional coordination of miR-125a, miR-125b, and miR-205 in breast cancer cells. Butcher Symposium, The University of Colorado Biofrontiers Institute, November 11, 2011
• Wang, S., Huang, X., Lee, C-K., and Liu, B. Therapeutic potential of the HDAC inhibitor SNDX-275 against erbB2-overexpressing, trastuzumab-resistant breast cancer. Postdoctoral Research Day, University of Colorado Anschutz Medical Campus, March 31st, 2011
• Liu B: Novel Mechanism of Herceptin Resistance in Breast Cancer - Signaling Network of ErbB2, ErbB3, and IGF-I Receptor. BIT Life Sciences’ 4th Annual World Cancer Congress – Collaborative Actions against Cancer. Dalian, China, May 25, 2011
• Bo Cai, Shuiliang Wang, Jingcao Huang, Choon-Kee Lee, Chunji Gao, and Bolin Liu. Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. American Journal of Translational Research 2013; 5(1):36-46.
• Wang, L., Huang, Z., Lin H., Li, Z., Hetzel, F.W., and Liu, B. Effects of photofrin-mediated photocytotoxicity on a panel of human pancreatic cancer cells. Photodiagnosis and Photodynamic Therapy, 2013 in press.
• Shuiliang Wang, Jingcao Huang, Hui Lyu, Choon-Kee Lee, Jianming Tan, Jianxiang Wang, and Bolin Liu. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death & Disease 2013 in press.
• Lee Y, Ma J, Lyu H, Huang J, Kim A, Liu B. Role of erbB3 receptors in cancer therapeutic resistance. Acta Biochim Biophys Sin (Shanghai). 2014 Mar;46(3):190-8. doi: 10.1093/abbs/gmt150. Epub 2014 Jan 20. Review. PubMed PMID: 24449784.
• Ma J, Lyu H, Huang J, Liu B. Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer. 2014 May 8;13:105. doi: 10.1186/1476-4598-13-105. Review. PubMed PMID: 24886126; PubMed Central PMCID: PMC4022415.
• Zhu P, Davis M, Blackwelder AJ, Bachman N, Liu B, Edgerton S, Williams LL, Thor AD, Yang X. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila). 2014 Feb;7(2):199-210. doi: 10.1158/1940-6207.CAPR-13-0181. Epub 2013 Dec 9. PubMed PMID: 24322659.
• Milgroom A, Intrator M, Madhavan K, Mazzaro L, Shandas R, Liu B, Park D. Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent. Colloids Surf B Biointerfaces. 2014 Apr 1;116:652-7. doi: 10.1016/j.colsurfb.2013.10.038. Epub 2013 Nov 1. PubMed PMID: 24269054.
• Jingcao Huang, Hui Lyu, Jianxiang Wang, and Bolin Liu. MicroRNA regulation and therapeutic targeting of Survivin in cancer. American Journal of Cancer Research 2015;5(1):20-31.
• Jingcao Huang, Hui Lyu, Jianxiang Wang, and Bolin Liu. MicroRNA regulation and therapeutic targeting of Survivin in cancer. American Journal of Cancer Research 2015;5(1):20-31.
• Wang, S., Huang, J., Lee, C-K., and Liu, B. The HDAC inhibitor entinostat targets erbB2/erbB3 receptors via functional cooperation of miR-125a, miR-125b, and miR-205 in breast cancer cells (LB-473). Proceedings Supplement: Late-Breaking Abstracts of AACR (p153) 2012
• Jingcao Huang, Hui Lyu, Jianxiang Wang, and Bolin Liu. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. Cancer Letters 2015; 366: 160-172.
• Hui Lyu, Jingcao Huang, Susan M Edgerton, Ann D Thor, Zhimin He, and Bolin Liu. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. International Journal of Clinical and Experimental Pathology 2015;8(6):6143-6156
• Hui Lyu, XiaoHe Yang, Susan M. Edgerton, Ann D. Thor, Xiaoying Wu, Zhimin He, and Bolin Liu. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells. Oncotarget 2015
• Michael A. Gordon, Nicholas D’Amato, Haihua Gu, Bolin Liu, Anthony Elias, and Jennifer K. Richer. The Anti-Androgen Enzalutamide Synergizes with Trastuzumab and Everolimus to Inhibit Breast Cancer Growth via Distinct Mechanisms [abstract]. Oral poster preview presentation, In: Proceedings of the 97th Annual Meeting and Expo of Endocrine Society, March 5-8, 2015, San Diego, CA
• Huang, J., Lyu, H., and Liu, B. The erbB3 blocking antibody MM-121 re-sensitizes trastuzumab-resistant breast cancer cells to trastuzumab-mediated antitumor activity in vitro and in vivo. Annual Retreat, University of Colorado Cancer Center, October 30th, 2012
• Jingcao Huang, Hui Lyu, Ying Wu, and Bolin Liu. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015, Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; 2015. Abstract nr 2532.
• Bo Cai, Jingcao Huang, Choon-Kee Lee, and Bolin Liu. Combination of Bendamustine and the HDAC Inhibitor Entinostat Enhances Apoptosis and DNA Damage Response in Multiple Myeloma Cells. The AACR special conference on Molecularly Targeted Therapies: Mechanisms of Resistance. San Diego, CA, May 9-12, 2012.
• Shuiliang Wang, Ling Zhu, Zhiyong Zeng, Lianghu Huang, Fengjin Lin, Rong Lin, Jin Wang, Jun Lu, Qinghua Wang, Lingjing Lin, Huiyue Dong, Weizhen Wu, Kai Zheng, Jinquan Cai, Shunliang Yang, Shixin Ye, Wei Liu, Yinghao Yu, Jianming Tan, and Bolin Liu. Epigenetic targeting of survivin enhances paclitaxel-mediated antitumor activity against non-small-cell lung cancer [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015, Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; 2015. Abstract nr 5382.
• Lyu, H., Huang, JC, Wu, Y., and Liu, B. Targeting of erbB3 with functional cooperative miRNAs enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells. Postdoctoral Research Day, University of Colorado Anschutz Medical Campus, March 12, 2015
• Lyu, H., Huang, JC, Wu, Y., and Liu, B. Targeting of erbB3 with functional cooperative miRNAs enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells. Oral presentation in Cancer Biology Graduate Program Annual Retreat, Colorado Springs, CO, November 7, 2015
• Shuiliang Wang, Ling Zhu, Weimin Zuo, Zhiyong Zeng, Lianghu Huang, Fengjin Lin, Rong Lin, Jin Wang, Jun Lu, Qinghua Wang, Lingjing Lin, Huiyue Dong, Weizhen Wu, Kai Zheng, Jinquan Cai, Shunliang Yang, Yujie Ma, Shixin Ye, Wei Liu, Yinghao Yu, Jianming Tan, and Bolin Liu. Overexpression of Survivin in non-small-cell lung cancer via epigenetic silencing of miR-203 [Abstract B06]. The AACR Special Conference - New Horizons in Cancer Research. Shanghai, China Nov 12-15, 2015.
• Lyu, H., Huang, JC, Wang, S., Yang, XP, Edgerton, S.M., Thor, A.D., and Liu, B. The erbB3 blocking antibody MM-121 overcomes resistance and enhances efficacy of paclitaxel against erbB2-overexpressing breast cancer. Postdoctoral Research Day, University of Colorado Anschutz Medical Campus, March 22, 2013
• Hui Lyu, XiaoHe Yang, Susan M. Edgerton, Ann D. Thor, Xiaoying Wu, Zhimin He, and Bolin Liu. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells. Oncotarget 2016;7(3): 2921-2935
• Ming Zhao, Erin W. Howard, Amanda B. Parris, Zhiying Guo, Qingxia Zhao, Zhikun Ma, Ying Xing, Bolin Liu, Susan M. Edgerton, Ann D. Thor, and Xiaohe Yang. Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells. Oncotarget, 2017, 8(35): 58847-58864 doi.org/10.18632/oncotarget.19375
• Michael A. Gordon, Nicholas C. D'Amato, Haihua Gu, Beatrice Babbs, Julia Wulfkuhle, Emanuel F. Petricoin, Isela Gallagher, Ting Dong, Kathleen Torkko, Bolin Liu, Anthony Elias and Jennifer K. Richer. Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer. Molecular Cancer Therapeutics, 2017;16(7):1389-1400. doi: 10.1158/1535-7163.MCT-17-0111.
• Hui Lyu, Jingcao Huang, Zhimin He, and Bolin Liu. Epigenetic mechanism of Survivin dysregulation in human cancer. Science China Life Sciences in press
• Shuiliang Wang, Ling Zhu, Weimin Zuo, Zhiyong Zeng, Lianghu Huang, Fengjin Lin, Rong Lin, Jin Wang, Jun Lu, Qinghua Wang, Lingjing Lin, Huiyue Dong, Weizhen Wu, Kai Zheng, Jinquan Cai, Shunliang Yang, Yujie Ma, Shixin Ye, Wei Liu, Yinghao Yu, Jianming Tan, and Bolin Liu. MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer. Oncotarget 2016;7(25): 37693-37713
• Ying Wu, Hui Lyu, Hongbing Liu, Xuefei Shi, Yong Song, and Bolin Liu. Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer. Scientific Reports 2016; 6: 31093
• Hui Lyu, Ying Wu, Yan Zhou, and Bolin Liu. Stat3 signaling in erbB3-mediated epithelial-to-mesenchymal transition in erbB2-positive breast cancer cells [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016, Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; 2016. Abstract nr 1593.
• Ling Zhu, Jin Wang, Weimin Zuo, Rong Lin, Tingting Lin, Hui Lyu, Bolin Liu, Jianming Tan, and Shuiliang Wang. Mesenchymal stem cells drive paclitaxel-resistance in erbB2-overexpressing breast cancer cells via paracrine signaling of NRG-1/erbB3 [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016, Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; 2016. Abstract nr 4091.